AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
🇿🇦
Secukinumab in South Africa
4 products registered with SAHPRA — 4 active
| Brand / Product | Reg. No. | Holder | Status | Expires |
|---|---|---|---|---|
| COSENTYX 150 mg/ml | 49/30.1/0233 | Novartis South Africa (Pty) Ltd | active | 12 Jun 2030 |
| SCAPHO 150 mg | 49/30.1/0232 | Novartis South Africa (Pty) Ltd | active | 16 Oct 2029 |
| COSENTYX 75 mg/0,5 ml SOLUTION FOR INJECTION | 56/30.1/0243 | Novartis South Africa (Pty) Ltd | active | 6 Sept 2027 |
| COSENTYX 300 mg/2 ml SOLUTION FOR INJECTION | 56/30.1/0242 | Novartis South Africa (Pty) Ltd | active | 6 Sept 2027 |
Secukinumab — SAHPRA Registration Details
SAHPRA (South Africa) has 4 registered products containing Secukinumab, of which 4 are currently active. Data is sourced directly from the official SAHPRA drug register and refreshed daily.
Track Secukinumab registration expiry dates, monitor competitor approvals, and receive alerts when registration status changes. Create a free account to set up portfolio monitoring.